Targeting the Aryl Hydrocarbon Receptor to Address the Challenges of Atopic Dermatitis.
J Drugs Dermatol
; 23(2): 23-28, 2024 Feb 01.
Article
in En
| MEDLINE
| ID: mdl-38306128
ABSTRACT
Atopic dermatitis (AD) is a chronic relapsing–remitting disease with a multifactorial etiology involving epidermal barrier and immunologic dysfunction. Topical therapies form the mainstay of AD treatment, but options are limited by adverse effects and restrictions on application site, duration, and extent of use. Tapinarof (VTAMA; Dermavant Sciences, Inc.) is a first-in-class, non-steroidal, topical aryl hydrocarbon receptor (AhR) agonist approved for the treatment of plaque psoriasis. AhR is a ligand-dependent transcription factor with wide-ranging roles, including regulation of homeostasis and immune response in skin cells. AhR expression and signaling are altered in many inflammatory skin diseases, and clinical trials with tapinarof have validated AhR as a therapeutic target capable of delivering significant efficacy. Tapinarof cream 1% once daily demonstrated efficacy versus vehicle in adults and adolescents with AD and is being investigated in the ADORING trials for the treatment of AD in adults and children down to 2 years of age. J Drugs Dermatol. 2024;23(2)23-28. doi10.36849/JDD.8026.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Stilbenes
/
Dermatitis, Atopic
Limits:
Humans
Language:
En
Journal:
J Drugs Dermatol
Journal subject:
DERMATOLOGIA
Year:
2024
Document type:
Article
Country of publication:
United States